Pepe Salvatore, Marasco Silvana F, Haas Steven J, Sheeran Freya L, Krum Henry, Rosenfeldt Franklin L
CJOB Department of Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia.
Mitochondrion. 2007 Jun;7 Suppl:S154-67. doi: 10.1016/j.mito.2007.02.005. Epub 2007 Mar 16.
In this review we summarise the current state of knowledge of the therapeutic efficacy and mechanisms of action of CoQ(10) in cardiovascular disease. Our conclusions are: 1. There is promising evidence of a beneficial effect of CoQ(10) when given alone or in addition to standard therapies in hypertension and in heart failure, but less extensive evidence in ischemic heart disease. 2. Large scale multi-centre prospective randomised trials are indicated in all these areas but there are difficulties in funding such trials. 3. Presently, due to the notable absence of clinically significant side effects and likely therapeutic benefit, CoQ(10) can be considered a safe adjunct to standard therapies in cardiovascular disease.
在本综述中，我们总结了辅酶Q10在心血管疾病中的治疗效果及作用机制的当前知识状态。我们的结论如下：1. 有证据表明，单独使用辅酶Q10或在标准治疗基础上加用辅酶Q10，对高血压和心力衰竭有有益作用，但在缺血性心脏病方面的证据较少。2. 所有这些领域都需要大规模多中心前瞻性随机试验，但为这类试验提供资金存在困难。3. 目前，由于明显没有临床显著副作用且可能有治疗益处，辅酶Q10可被视为心血管疾病标准治疗的安全辅助药物。
